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ABSTRACT
BACKGROUND: Studies have shown signal intensity (SI) changes in brains of children 
exposed to repeated doses of gadolinium-based contrast agent (GBCA). HYPOTHESIS: 
Trajectory of changes in relative dentate nucleus (DN) and globus pallidus (GP) SI in children 
receiving multiple doses of GBCA will alter when switched from linear to macrocyclic agents. 
STUDY TYPE: retrospective longitudinal. POPULATION: 35 children, age range [0.5-17.0] 
years, undergoing brain tumor follow-up between 2006 and 2017. FIELD 
STRENGTH/SEQUENCE: Unenhanced T1WI, serial scans at both 1.5 and 3 Tesla. 
ASSESSMENT: Regions-of-interest were drawn on DN, GP, and SI’s normalized to middle 
cerebellar peduncle (DN/MCP) and cerebral white-matter (GP/CWM) respectively. Change 
in SI ratios as a function of dose (slope gradient) calculated according to type of contrast 
agent received: linear only, macrocyclic only, or switchover from linear to macrocyclic. For 
the latter, gradients were compared before and after switchover. The effect of anticancer 
treatment on slope gradient was tested. STATISTICAL TESTS: One-sample t- or Mann-
Whitney U- tests for slope gradients differing from zero. Independent samples t-tests to 
compare slope gradient groups. Paired sample t-tests to compare slope gradients before 
and after switchover. RESULTS: A significant (p<0.05)  increase in SI ratio was observed 
following multiple doses of linear but not macrocyclic agents: mean percentage increase per 
dose in SI was 0.063% vs -0.034% for DN/MCP, and 0.078% vs 0.004% for GP/CWM ratios. A 
significant (p<0.05) change of SI trajectory in DN/MCP ratio was demonstrated when 
switching from linear to macrocyclic agent. There was no difference in SI trajectory between 
patients who had anticancer therapies and those who did not, DN/MCP p =0.740; GP/BWM 
p =0.694. DATA CONCLUSION: Switching from linear to macrocyclic gadolinium-based 
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contrast agents seems to halt relative T1 signal increase in deep gray-matter in children. 
Anticancer treatments appeared to have no impact on trajectory of T1 SI.
Keywords
Contrast agent, gd deposition, brain, pediatrics, mri
INTRODUCTION
The first intravenous gadolinium-based contrast agent (GBCA) for MR Imaging was licensed 
globally for clinical use in 1988 (1). Apparent deposition of gadolinium in the brain following 
repeated doses of GBCA was recognized in 2014, by Kanda et al (2). The authors reported a 
correlation between increased signal intensity within the dentate nucleus (DN) and globus 
pallidus (GP) and the number of doses of GBCA received.
Several studies have shown signal intensity changes in the brains of children exposed 
to repeated doses of GBCAs (3, 4, 13, 5–12). This is important because pediatric patients 
(assuming a normal life expectancy) have a longer period over which neurotoxicity can act or 
become manifest and be more likely to receive further doses of gadolinium throughout their 
lifetime.
Relative T1 hyperintensity in the DN has also been attributed to the treatment effects 
of chemotherapy or radiation-therapy (13) A recent study reported changes in signal intensity 
in the DN and GP in children with brain tumors undergoing brain irradiation that are 
independent of the administration of GBCA (14) and another suggests increased R1 values in 
adults undergoing brain irradiation may increase susceptibility to gadolinium deposition (15).
The primary hypothesis for this study is that the trajectory of progressive changes in 
relative DN and GP signal intensity in children receiving multiple doses of GBCA for brain 
tumor follow-up will change when the child is switched from a linear to a macrocyclic GBCA. 
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Testing of this hypothesis by retrospective analysis has been enabled by a change in 
institutional GBCA administration policy. Until 2009 pediatric patients at our institution were 
administered the linear GBCA gadopentetate dimeglumine (Magnevist, Bayer Healthcare, 
Berlin, Germany) because this was the only contrast agent licensed for use in young children 
in the UK. In 2009 the macrocyclic agent gadobutrol, (Gadovist, Bayer Healthcare, Berlin, 
Germany) was licensed in the UK for children over seven years old. In 2012 it was licensed for 
children of 2 years old and above and in 2015 it was licensed for children less than two years 
of age (16). Our institution followed these timelines so that where contrast agent was 
administered the patient would have received either linear or macrocyclic GBCA, depending 
on the date of the scan and the age of the child. Over the period of the retrospective analysis 
the MR imagers used for scanning pediatric patients and the basic MRI sequence protocol for 
pediatric brain tumor evaluation remained unchanged.
Given the uncertainty about the relationship between treatment effects on deep gray 
matter signal intensity in children receiving multiple doses of GBCA, we test a secondary 
hypothesis that children receiving chemotherapy and/or radiation therapy will show a 
steeper trajectory of relative T1-weighted signal increases in the DN and GP than children 
receiving no active treatment or surgery alone. An exploratory analysis of the effect of GBCA 
type (linear or macrocyclic) on relative T1-weighted signal trajectories for these two patient 
groups is also conducted.
MATERIALS AND METHODS
Consent was obtained from the parent/guardian of all participants included in this study for 
their clinical data to be collated and analyzed as part of an on-going research study approved 
by the UK National Health Service Research Ethics Committee (04/MRE04/41).
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Participants were pediatric brain tumor patients treated at the Nottingham University 
NHS Trust and imaged between 2006 and 2017. Participants were included in the analysis if 
they had undergone MRI with 6 doses or more of either linear GBCA, macrocyclic GBCA or 
both, with an MRI protocol that included an unenhanced axial T1WI sequence and were under 
18 years of age at the time of their first scan. Potential participants were excluded if they had 
a condition known to be associated with abnormal DN or GP signal on MRI; if they had brain 
lesions or surgical resection involving the DN or GP; or if they had previously undergone MRI 
outside our institution with a GBCA that could not be identified. Individual MR scans were 
excluded from the analysis if they originated from other institutions, did not include an 
unenhanced axial T1WI and if degraded by either patient motion or flow artifacts obscuring 
the anatomical structure of interest. A history of chemotherapy or radiation therapy 
administration was obtained from the clinical notes. Screening of the patients prior to their 
MRI scan should have ensured that none of the patients had renal impairment; however 
nuclear medicine and blood test results were also checked. Medical records were checked to 
identify any other reasons for exclusion as were their series of MRI scans.
Thirty five patients were analyzed in total. For the purposes of analysis, 3 participant 
sub-groups were defined based on GBCA administration: (1) The ‘linear-only’ group includes 
all those who received 6 or more doses of gadopentetate dimeglumine, but the analyzes 
referring to this group include only the signal intensity ratios prior to their first dose of 
gadobutrol (if given); (2) the ‘macrocyclic-only group’ includes participants who only received 
gadobutrol (i.e. no exposure to gadopentetate dimeglumine) and received 6 or more doses 
of gadobutrol; (3) the ‘switchover group’ included those who received 6 or more doses of 
gadopentetate dimeglumine followed by 3 or more doses of gadobutrol (and could therefore 
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include patients already in the linear-only group). Evolution of the different groups is 
described in Figure 1.
MR Imaging Protocol
Scanning was performed on three scanners: an Intera 1.5 Tesla (Philips Healthcare, Best, The 
Netherlands); an Achieva 3 Tesla (Philips Healthcare, Best, The Netherlands) and a Signa Excite 
1.5 Tesla (General Electric Healthcare, Chicago, IL, USA). Our institution uses a set protocol 
which was employed to scan all pediatric brain tumor patients throughout the study period 
to maintain consistent parameters. Parameters for the axial T1WI spin echo sequence used 
for analysis are shown in Table 1. The GBCA dose was calculated strictly as per the 
manufacturers’ recommendation: 0.2ml (0.002mmol/ml) per kg of weight for gadopentetate 
dimeglumine and 0.1ml (1.0 mmol/ml) per kg for gadobutrol. The GBCA type and dose at each 
time point were recorded in and collected from our institution’s radiology information 
system. 
Image Analysis
Image viewing and analysis was performed using the GE Centricity Universal Viewer V6.0 PACS 
system (GE Healthcare, Chicago, IL, USA). The axial T1WI sets were scored for quality using a 
scoring range of 0 – 3. Images that were scored 0 were rejected from analysis.  A second 
independent reviewer (neuroradiologist with 14 years’ experience, RD) reviewed all included 
image slices to confirm that the images were appropriate for inclusion in the analysis. Regions 
of Interest (ROIs) were drawn manually by SR on the unenhanced axial T1WI, supplemented 
by reference to other T2WI to aid structure identification if required. The middle cerebellar 
peduncle (MCP) and the cerebral white matter (CWM) were selected as control regions for 
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ratio calculations based on the relative lack of evidence of gadolinium deposition in white 
matter compared to deep gray matter (17–19). An elliptical ROI was placed on the DN and 
GP. ROIs were standardized to between 0.3 and 0.6 cm in size depending on the size of the 
anatomy. Training and supervision by a neuroradiologist with 30 years’ experience, TJ, 
assisted in the identification of the individual structures and ensured accurate placement of 
ROIs. An example of the ROIs drawn can be seen in Figure 2.
Ratios of mean signal intensity were calculated for the DN relative to the MCP 
(DN/MCP) and for the GP relative to the CWM (GP/CWM). Intensity ratios were used to 
reduce confounding effects from the variation in data acquisition across different scanners 
and field strengths. For each subject, the ratios were normalized to their respective ratio at 
the first scan, and the gradient of the relative signal intensity ratio slope as the number of 
doses increased was calculated from linear regression (Microsoft Excel 2010, Redmond, WA, 
USA).
For the Switchover group, ratios were calculated for before, and after contrast agent 
switch. Gadopentetate dimeglumine ratios at each time point were normalized by their first 
scan values, and gadobutrol ratios by the last unenhanced T1WI, which was acquired 
immediately prior to the first dose of gadobutrol. 
Statistical Analysis
Statistical analysis was performed using SPSS version 21 (IBM SPSS Statistics for Windows, 
Version 21.0. Armonk, NY, USA). A one-sample t-tests or Mann-Whitney U tests, depending 
on normality, were performed to test for slope gradients differing from zero. Group 
comparisons of signal intensity ratio slope gradients were made using independent samples 
t-tests. In the switchover group, differences between slopes before and after changing the 
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contrast agent were compared using paired sample t-tests. P values below 0.05 were 
considered statistically significant.
RESULTS
Of the 65 patients identified as suitable subjects, whose parents / care takers had consented 
to data collection, 35 individuals fulfilled the inclusion criteria for this analysis and 28 were 
excluded based on the exclusion criteria. A further two potential participants had individual 
scans without unenhanced T1WIs which put them below the required number of scans for 
inclusion. Out of the 35 patients selected, it was possible to analyze both the DN and GP in 18 
subjects, only DN in 8 subjects and only GP in 9 subjects. This was because some had 
lesions/surgery in one area but not the other. Details of the 35 included participants are 
shown in Table 2.
A subgroup 18 patients that were scanned more 3 or more times each at 1.5 and 3 
Tesla using the same contrast agent. The agreement of ratios calculated from 1.5 Tesla images 
only compared to those calculated from 3 Tesla images only can be seen in the Bland-Altman 
plot of Figure 3.
For the whole group, positive slope gradients were observed with the distribution of 
slope gradients varying significantly from ‘no slope’ for both DN/MCP (mean ± standard 
deviation (SD) = 0.002 ±0.005, p =0.026, t =2.360) and GP/CWM, (mean ± SD =0.004 ±0.005 p 
<0.005, t =4.271. The mean percentage increase in signal intensity per dose across the group 
was 0.013% ±0.043 (SD), for the DN/MCP ratio and 0.027% ±0.041 for the GP/CWM ratio.
The data was then split into the ‘linear only’ and ‘macrocyclic only’ groups. Analysis of 
the linear group showed positive slope gradients with the distribution of slope gradients 
varying significantly from ‘no slope’ for both DN/MCP (mean ± SD = 0.007 ±0.004, p<0.005, t 
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=8.618) and GP/CWM (p <0.005, t =6.07) (see Figure 4a for an example of a linear group 
patient). The mean percentage increase per dose in signal intensity across the group was 
0.063% ±0.044 for the DN/MCP ratio, and 0.078% ±0.082. 
In contrast, the macrocyclic group showed no clear slope, confirmed by the lack of 
significant difference from the ‘no-slope’ condition in the one-sample t-test for either 
DN/MCP (p =0.104, t =-1.870) or GP/CWM (p =0.546, t =0.628) (see Figure 4b for an example 
of a macrocyclic group patient). The mean percentage increase per dose in signal intensity 
across the group was -0.034% ±0.051 for the DN/MCP ratio and 0.004% ±0.040 for the 
GP/CWM.
For the whole group an independent samples t-test demonstrated no significant 
difference in the T1WI signal intensity ratio slope gradient between those who did and those 
who did not receive chemotherapy or radiation therapy, for neither DN/MCP or GP/CWM 
ratios (DN/MCP p =0.740, t =-0.337; GP/BWM p =0.694, t =0.399). The percentage increase 
per dose for the whole group was 0.011% ±0.043 for the DN/CWM and 0.024% ±0.043. When 
the analysis was repeated for the linear group separately, the independent Mann-Whitney U 
test again showed no significant difference between those who did and those who did not 
receive chemotherapy and/or radiation therapy (linear group: DN/MCP p =0.246, GP/CWM p 
=0.733; macrocyclic group: DN/MCP p =0.385, GP/CWM p =0.703). For the patients who 
received no therapy and were in the linear group the percentage increase per dose was 
0.092% ±0.035 for the DN/CWM and 0.137% ±0.113 for the GP/CWM ratio. Those who had 
received therapy and were in the linear group showed a percentage increase per dose of 
0.044% ±0.039 for the DN/CWM ratio and 0.045% ±0.030 for the GP/CWM ratios.
For the Switchover group, the paired samples t-test showed a significant difference in 
the distribution of slope gradients before and after the switch from linear to macrocyclic for 
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DN/MCP (p =0.014), with the plot demonstrating an apparent reversal from increasing to 
decreasing trajectory of ratios at the point of switch (Figure 5a). No significant difference was 
seen in the distribution of slope gradients before and after the switch for GP/CWM (p =0.680), 
however inspection of the plot reveals a plateauing of the trajectory of ratios at the point of 
the switch (Figure 5b) but a noticeably larger standard deviation.
DISCUSSION
We hypothesized that the trajectory of progressive changes in relative DN and GP signal 
intensity in children receiving multiple doses of GBCA will change when switching from a 
linear to a macrocyclic GBCA. This hypothesis is supported with regard to the DN/MCP ratios, 
where a significant difference in slope gradients was identified in children before and after 
the switchover. Two other studies in adults have evaluated serial linear and subsequent 
macrocyclic doses in the same patients with similar findings (20, 21). Although no statistically 
significant change in trajectory was found for the GP/CWM ratios before and after the 
switchover, the plot of mean values shows a plateauing of the trajectory after the switch to 
macrocyclic GBCA.
Our data for the separate linear and macrocyclic groups also demonstrates different 
trajectories of signal change; the linear group showed positive slope gradients in keeping with 
presumed gadolinium deposition at both sites (DN and GP), whereas the macrocyclic group 
did not. The findings are in line with the majority of recent literature identifying increase in 
T1-weighted hyperintensity in the GP and DN after serial doses of linear GBCAs but not 
macrocyclic GBCAs (2, 4–7, 11, 13, 22, 23).
A notable finding was the negative slope gradient for DN/MCP ratios in the switchover 
group after the change to macrocyclic GBCA. This finding agrees with the two studies in adults 
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that made use of a change in the type of contrast agent (20, 21). It is difficult to specify the 
reason for this decline. It has been demonstrated that macrocyclic GBCAs also deposit in the 
brain but to a lesser extent than linear agents (24) and few studies have reliably demonstrated 
signal intensity ratio increases in the macrocyclic group (25). Studies in rats demonstrated 
that gadolinium found in the rat brain after linear and macrocyclic contrast administration 
was in three distinct forms, intact GBCA, soluble macromolecules and in insoluble form, the 
intact GBCA being identified as macrocyclic contrast (26, 27). This suggests that the reason 
for the decline in signal intensity ratio therefore could relate to a steady washout of the linear 
gadolinium, which has been demonstrated in rats (28). Changes to the binding of the 
gadolinium; dechelation and precipitation of the gadolinium is another consideration (29). 
Alternatively, this decline in ratio values could be due to a disproportionate increase in signal 
intensity of the control ROI used in the ratio calculation, the MCP. This latter point highlights 
a problem with much of the existing literature that uses signal intensity ratios; i.e. the 
assumption that the control ROI is not subject to gadolinium deposition. For example, several 
previous studies use the pons as a control ROI for the DN (2, 7, 8, 10, 11, 17, 23), but it is 
recognized that the pons, which contains many gray matter nuclei, is a site of gadolinium 
deposition itself (13). Our data do not allow isolation of the separate effects of potential 
gadolinium clearance from the DN and gadolinium deposition in the MCP to be disentangled, 
for which quantitative T1-mapping would be required.
The values for DN/MCP and GP/CWM increased with GBCA dose number for our 
pediatric cohort as a whole, which broadly confirms the findings of other groups studying 
pediatric populations (3, 4, 6, 8–14). However, we found no significant difference in the 
trajectory of signal intensity ratio increase between children treated with chemotherapy and 
radiation therapy and those who received no treatment or surgery alone. These findings are 
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in line with another study in adults and children which found that radiation therapy had no 
impact on signal intensity change (5), but conflict with a recent study showing that signal 
intensity changes in the DN and GP occur in patients with brain tumors undergoing brain 
irradiation independent of GBCA administration (14).
Our analysis is limited by a relatively small sample size, particularly when the sample 
is split into groups for analysis. It would not be ethical to conduct a prospective trial testing 
the relative gadolinium deposition rates in children following multiple GBCA doses, and hence 
we were limited to conducting a retrospective analysis. One strength of our study is that 
during the study period (2006 to 2017) the MRI scanners used at our institution for pediatric 
brain tumor evaluation, and the basic MRI sequence protocol, did not change which provides 
continuity in the dataset. Although patients were scanned on both 1.5 and 3 Tesla scanners, 
the use of signal intensity ratios removes confounding effects.
To date, brain deposition of gadolinium has not been shown to be harmful in the 
majority of patients and the long-term consequences are unknown. Our data do not allow us 
to explore the consequences of presumed gadolinium deposition for the children involved. 
Apart from the fact that we do not have quantitative cognitive or neurological function scores 
for these children, this group is likely to carry a significant neurological and cognitive burden 
due to their complex neurosurgical and treatment histories. In addition, maturation of brain 
structure and function occurs throughout childhood and hence gadolinium deposition may 
affect the developing brain differently to a mature adult brain. However, it is important that 
the consequences of gadolinium deposition are studied prospectively as detrimental effects 
could be greater in the developing brain that is undergoing rapid structural and functional 
maturation compared to the mature adult brain.
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In conclusion our analyzes confirm previous reports that T1 signal increase occurs in 
the deep gray matter following repeated doses of linear GBCA but not macrocyclic agents. 
Furthermore, we demonstrate that switching from linear to macrocyclic GBCAs halts the 
relative T1 signal increase in deep gray matter of children with brain tumors. We found no 
evidence of an independent effect of chemotherapy or radiation therapy on the trajectory of 
T1 signal increase.
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Tables
Table 1: Parameters for axial T1WI spin echo imaging
Imager
Field 
Strength 
(Tesla)
NS
A
Matrix
Slice 
thickness 
(mm)
Flip 
angle 
(°)
FOV
(mm)
TR (ms)
TE 
(ms)
Philips 
Intera
1.5 2 205x256 4 68 - 95 230-250
500 – 
900
10-25
Philips 
Achieva
3 1 205x256 4 68 - 95 230-250
500 – 
900
10-25
GE 
Signa 
Excite
1.5 2 224x320 4 68 - 95 230-250
500 – 
900
10-25
TR = repetition time; TE = echo time; NSA = number of signal averages; FOV = field of view
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Table 2: Characteristics of the participants included in the analysis. 
Total Group
Magnevist Gadovist Switchover
Number of participants 35 25 10 13
Age [years] at 1st scan – mean 
± SD [range]
8.13 ±4.64
[0.5-17.0]
6.50 ±4.12
[0.5-14.0]
12.30 ±3.10
[8.0-17.0]
7.41 ±3.96
[0.75-14.0]
Age [years] at switchover 
from Magnevist to Gadovist 
mean ± SD [range]
N/A N/A N/A 14.0 ± 3.5
[6-21]
Male/female 16/19 10/15 6/4 6/7
Number of doses - mean  S.D 
[range]
15.48 ±5.96
[7-32]
17.44 ±5.82
[9-32]
10.60 ±2.54
[7-16]
19 ±5.82
[11-32]
Chemo/radiation therapy n=21 n=14 n=7 N/A
No chemo/radiation therapy n=14 n=11 n=3 N/A
DN/MCP n=26 n=18 n=8 n=10
GP/CWM n=27 n=17 n=10 n=8
SD = standard deviation, DN = dentate nucleus, GP = globus pallidus, MCP = middle 
cerebellar peduncle, CWM = cerebral white matter.
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Figure Legends
Figure 1- Flow chart showing patient group numbers as derived from the exclusion process, 
the number of scans analyzed and rejected and the patients’ diagnoses. DN = Dentate 
Nucleus, GP = Globus Pallidus.
Figure 2 – Examples of region of interest (ROI) placement for (a) right dentate nucleus (b) 
right middle cerebellar peduncle, (c) right globus pallidus, (d) cerebral white matter. All ROIs 
were placed on pre-contrast axial T1-weighted images.
Figure 3 – Bland-Altman plot comparing signal intensity ratio slope gradients for patients 
that were scanned more 3 or more times each at 1.5 and 3 Tesla using the same contrast 
agent. Apart from 2 outliers, all repeated measurements are within the 95% limits of 
agreement, and most present very small differences when measured with either a 1.5 or a 3 
Tesla scanner.
Figure 4 – Individual subject data for relative globus pallidus (GP) / cerebral white matter 
(CWM) T1 signal intensity ratios for (a) a patient from the linear group and (b) a patient 
from the macrocyclic group.  DN/MCP and GP/CWM ratios for each dose are expressed 
relative to the respective values derived from the unenhanced T1-weighted image prior to 
the first dose of gadolinium based contrast agent (GBCA).
Figure 5 – Group mean values (n=18) for each dose and fitted slopes from the switchover 
group for the relative (a) dentate nucleus (DN) / middle cerebellar peduncle (MCP) and (b) 
S.
I.R
at
io
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globus pallidus (GP) / cerebral white matter (CWM) T1 signal intensity ratios before (dashed 
line) and after (dash-dot line) the switch from linear to macrocyclic.  For each patient, the 
intensity ratios of the linear group are normalized by the ratio of the last linear contrast 
agent scan, and macrocyclic ratios by the ratio of their first macrocyclic scan, so that both 
those scans are plotted at (0,1).  The gray area represents the standard deviation around the 
mean values.
Page 26 of 34
Journal of Magnetic Resonance Imaging
Journal of Magnetic Resonance Imaging
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FOR PEER REVIEW
 ONLY
 
Flow chart showing patient group numbers as derived from the exclusion process, the number of scans 
analyzed and rejected and the patients’ diagnoses. DN = Dentate Nucleus, GP = Globus Pallidus. 
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Examples of region of interest (ROI) placement for (a) right dentate nucleus (b) right middle cerebellar 
peduncle, (c) right globus pallidus, (d) cerebral white matter. All ROIs were placed on pre-contrast axial T1-
weighted images. 
101x116mm (600 x 600 DPI) 
Page 28 of 34
Journal of Magnetic Resonance Imaging
Journal of Magnetic Resonance Imaging
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FOR PEER REVIEW
 ONLY
 
Bland-Altman plot comparing signal intensity ratio slope gradients for patients that were scanned more 3 or 
more times each at 1.5 and 3 Tesla using the same contrast agent. Apart from 2 outliers, all repeated 
measurements are within the 95% limits of agreement, and most present very small differences when 
measured with either a 1.5 or a 3 Tesla scanner. 
86x50mm (300 x 300 DPI) 
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Individual subject data for relative globus pallidus (GP) / cerebral white matter (CWM) T1 signal intensity 
ratios for (a) a patient from the linear group and (b) a patient from the macrocyclic group.  DN/MCP and 
GP/CWM ratios for each dose are expressed relative to the respective values derived from the unenhanced 
T1-weighted image prior to the first dose of gadolinium based contrast agent (GBCA). 
87x129mm (300 x 300 DPI) 
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Group mean values (n=18) for each dose and fitted slopes from the switchover group for the relative (a) 
dentate nucleus (DN) / middle cerebellar peduncle (MCP) and (b) globus pallidus (GP) / cerebral white 
matter (CWM) T1 signal intensity ratios before (dashed line) and after (dash-dot line) the switch from linear 
to macrocyclic.  For each patient, the intensity ratios of the linear group are normalized by the ratio of the 
last linear contrast agent scan, and macrocyclic ratios by the ratio of their first macrocyclic scan, so that 
both those scans are plotted at (0,1).  The gray area represents the standard deviation around the mean 
values. 
86x137mm (300 x 300 DPI) 
Page 31 of 34
Journal of Magnetic Resonance Imaging
Journal of Magnetic Resonance Imaging
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FOR PEER REVIEW
 ONLY
Image Quality
In a cohort of pediatric patients, it is difficult to obtain optimal image quality during 
MRI without using general anesthetic due to patient movement. In addition to this, 
flow artifact in the posterior fossa is a common feature. Many MR images were 
rejected for these reasons. Images were scored 0-3 where 0 = unacceptable quality 
or performed elsewhere; 1 = inferior quality but acceptable in the areas of analysis; 2 
= acceptable quality and 3 = optimal scan.
Supplementary Figures:
 
Supplementary Figure 1 -An example of category 0; pre-contrast axial T1-weighted scan with 
unacceptable movement artifact.
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Supplementary Figure 2 - An example of category 1; pre-contrast axial T1-weighted scan with some 
flow artifact but it is acceptable in the lower portion of the dentate nucleus.
Supplementary Figure 3 - An example of category 2; axial pre-contrast T1- weighted scan of 
acceptable quality with minimal artifact
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Supplementary Figure 4 - An example of category 3; axial pre-contrast T1-weighted scan of good 
quality
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